Cardioprotective interventions for cancer patients receiving anthracyclines
about
Flavaglines alleviate doxorubicin cardiotoxicity: implication of Hsp27Cardioprotective interventions for cancer patients receiving anthracyclinesHeart failure in chemotherapy-related cardiomyopathy: Can exercise make a difference?Recent Advances on Pathophysiology, Diagnostic and Therapeutic Insights in Cardiac Dysfunction Induced by Antineoplastic DrugsAGO Recommendations for Diagnosis and Treatment of Patients with Primary and Metastatic Breast Cancer. Update 2011.Cardiotoxicity of anticancer drugs: the need for cardio-oncology and cardio-oncological preventionCardiotoxicity of anthracycline agents for the treatment of cancer: systematic review and meta-analysis of randomised controlled trialsDexrazoxane for preventing anthracycline cardiotoxicity in children with solid tumors.Moving forward with new data and approaches: a fresh look at anthracyclines in non-Hodgkin's lymphoma.Dexrazoxane may prevent doxorubicin-induced DNA damage via depleting both topoisomerase II isoforms.Evaluation of lecithinized human recombinant super oxide dismutase as cardioprotectant in anthracycline-treated breast cancer patientsAn update on cardio-oncology.Review of cardiotoxicity in pediatric cancer patients: during and after therapy.Dexrazoxane as a cardioprotectant in children receiving anthracyclinesCardiovascular complications of breast cancer therapy in older adultsSIOG (International Society of Geriatric Oncology) recommendations for anthracycline use in the elderly.Recommendations for cardiomyopathy surveillance for survivors of childhood cancer: a report from the International Late Effects of Childhood Cancer Guideline Harmonization Group.Strategies to prevent anthracycline-related congestive heart failure in survivors of childhood cancer.Effects of MnDPDP and ICRF-187 on Doxorubicin-Induced Cardiotoxicity and Anticancer ActivityA recommended practical approach to the management of anthracycline-based chemotherapy cardiotoxicity: an opinion paper of the working group on drug cardiotoxicity and cardioprotection, Italian Society of CardiologyAssessment of dexrazoxane as a cardioprotectant in doxorubicin-treated children with high-risk acute lymphoblastic leukaemia: long-term follow-up of a prospective, randomised, multicentre trialNew approaches in the management of advanced breast cancer - role of combination treatment with liposomal doxorubicin.Cardiovascular effects of noncardiovascular drugs.Drug-induced oxidative stress and toxicity.Dexrazoxane: a cardioprotectant for pediatric cancer patients receiving anthracyclines.Improving the preclinical models for the study of chemotherapy-induced cardiotoxicity: a Position Paper of the Italian Working Group on Drug Cardiotoxicity and Cardioprotection.Cardiac telomere length in heart development, function, and disease.Use of pattern recognition analysis to identify underlying relationships of Doxorubicin derivatives optimized for breast cancer treatment.Anthracyclines: a cornerstone in the management of non-Hodgkin's lymphomaKorean Guidelines for Diagnosis and Management of Chronic Heart Failure.Anthracycline cardiomyopathy is mediated by depletion of the cardiac stem cell pool and is rescued by restoration of progenitor cell function.Cardiovascular Complications of Cancer Therapy: Best Practices in Diagnosis, Prevention, and Management: Part 1.
P2860
Q21135010-602ADCBF-06DD-48E5-9ECC-2D5F741B8406Q24236338-21525E58-2922-49AB-8495-5D598F9474D5Q26740352-972DFC68-4783-48AB-A6A9-6646A5DA20F8Q28087776-A19D17DB-7EE9-46AE-B9FD-D6F7BFA88861Q30318240-B595CBCF-C12A-4BDC-A0EE-E9D4B5BF4620Q33574045-DD16B6AF-FF56-44D8-8624-80F69AB6F9D0Q33619867-FB0D4F84-14C5-47C2-B957-72B3EAEA3F7CQ34073681-2AACAA95-6381-40C4-9855-46A22236C98FQ34269228-34EACCA5-19DE-4A7A-8059-46B08E0744DAQ34565455-F1DA06B2-71C4-43C7-835F-C8FA399BF08DQ34570840-0C82554F-0766-4F70-AAD8-FD16FBD3B458Q34650059-97DE5114-AAE3-4648-9266-83DDC4850713Q35008126-67BEAE3E-8F8B-450E-877C-813642A17DB0Q35583768-04ED6DF2-C090-4243-8213-79DAB4052E34Q35584686-7F6BE9B5-6DDA-4A52-8E1E-B58F405B97EFQ35716026-8647FB39-231D-4833-B8B0-E533C8122730Q35797623-63B7AAFC-2E73-453F-BB09-D48BDB6F351EQ36184665-202F93D1-CE15-4B76-B9C8-BABA50AECD67Q36199841-C6E981E1-57A6-4EB8-BF29-71BA3806C386Q37052852-34121617-1FBE-4002-959A-91E7891951FAQ37129069-22CADE02-EE8D-4063-AA6E-1053E31D9CAAQ37355919-A24FAD54-AD97-46A3-B711-60C6A22BC1E2Q37413163-C0011371-69DA-4AFA-A682-A89B82C0CC3EQ38037517-E9B7F324-2742-4E58-AD3B-266C30B20206Q38264693-836FA479-D853-4674-9EE5-F1728893AED7Q38546114-674EA60B-3BED-4173-B2EA-DDB553C6E37FQ38678302-5B08B4C0-F071-4D32-8ADB-602528A39561Q38738908-EC280C36-97D2-4C25-B14D-B203B47A75A5Q40757934-984B9B26-D3F4-4614-A654-7EF29A92CF0AQ41686228-412E013A-5E78-4BF9-9111-02D45A4F17DAQ41883542-B41510EA-49B7-441F-A34E-E6DB2651DC6AQ45073135-0002F05F-D5E1-4C20-8744-FC08566A7AAE
P2860
Cardioprotective interventions for cancer patients receiving anthracyclines
description
2008 թուականի Ապրիլին հրատարակուած գիտական յօդուած
@hyw
2008 թվականի ապրիլին հրատարակված գիտական հոդված
@hy
article scientifique (publié 2008/04/23)
@fr
articolo scientifico (pubblicato il 2008/04/23)
@it
artigo científico (publicado na 2008/04/23)
@pt
artikull shkencor
@sq
artículu científicu espublizáu en 2008
@ast
scientific article (published 2008-04-23)
@en
vedecký článok (publikovaný 2008/04/23)
@sk
vetenskaplig artikel (publicerad på 2008/04/23)
@sv
name
Cardioprotective interventions for cancer patients receiving anthracyclines
@ast
Cardioprotective interventions for cancer patients receiving anthracyclines
@en
Cardioprotective interventions for cancer patients receiving anthracyclines
@en-gb
Cardioprotective interventions for cancer patients receiving anthracyclines
@nl
type
label
Cardioprotective interventions for cancer patients receiving anthracyclines
@ast
Cardioprotective interventions for cancer patients receiving anthracyclines
@en
Cardioprotective interventions for cancer patients receiving anthracyclines
@en-gb
Cardioprotective interventions for cancer patients receiving anthracyclines
@nl
prefLabel
Cardioprotective interventions for cancer patients receiving anthracyclines
@ast
Cardioprotective interventions for cancer patients receiving anthracyclines
@en
Cardioprotective interventions for cancer patients receiving anthracyclines
@en-gb
Cardioprotective interventions for cancer patients receiving anthracyclines
@nl
P2093
P2860
P3181
P1476
Cardioprotective interventions for cancer patients receiving anthracyclines
@en
P2093
Elvira C van Dalen
Huib N Caron
Leontien CM Kremer
P2860
P3181
P356
10.1002/14651858.CD003917.PUB3
P577
2008-04-23T00:00:00Z